Ovid Therapeutics (OVID) Competitors $1.48 -0.09 (-5.73%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$1.51 +0.03 (+2.03%) As of 10/17/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OVID vs. INBX, ATXS, CYRX, SLDB, ALMS, DRUG, LXEO, RAPT, AUTL, and CGEMShould you be buying Ovid Therapeutics stock or one of its competitors? The main competitors of Ovid Therapeutics include Inhibrx Biosciences (INBX), Astria Therapeutics (ATXS), CryoPort (CYRX), Solid Biosciences (SLDB), Alumis (ALMS), Bright Minds Biosciences (DRUG), Lexeo Therapeutics (LXEO), Rapt Therapeutics (RAPT), Autolus Therapeutics (AUTL), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry. Ovid Therapeutics vs. Its Competitors Inhibrx Biosciences Astria Therapeutics CryoPort Solid Biosciences Alumis Bright Minds Biosciences Lexeo Therapeutics Rapt Therapeutics Autolus Therapeutics Cullinan Therapeutics Ovid Therapeutics (NASDAQ:OVID) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends. Is OVID or INBX more profitable? Inhibrx Biosciences has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -574.44%. Ovid Therapeutics' return on equity of -58.87% beat Inhibrx Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Ovid Therapeutics-574.44% -58.87% -43.18% Inhibrx Biosciences N/A -137.83%-76.31% Which has higher valuation & earnings, OVID or INBX? Inhibrx Biosciences has lower revenue, but higher earnings than Ovid Therapeutics. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOvid Therapeutics$6.65M15.82-$26.43M-$0.53-2.79Inhibrx Biosciences$200K2,696.90$1.69B-$10.58-3.52 Do institutionals and insiders have more ownership in OVID or INBX? 72.2% of Ovid Therapeutics shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 13.1% of Ovid Therapeutics shares are owned by company insiders. Comparatively, 17.1% of Inhibrx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts rate OVID or INBX? Ovid Therapeutics presently has a consensus price target of $3.70, suggesting a potential upside of 150.00%. Given Ovid Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Ovid Therapeutics is more favorable than Inhibrx Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ovid Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86Inhibrx Biosciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Does the media refer more to OVID or INBX? In the previous week, Ovid Therapeutics' average media sentiment score of 0.00 equaled Inhibrx Biosciences'average media sentiment score. Company Overall Sentiment Ovid Therapeutics Neutral Inhibrx Biosciences Neutral Which has more risk and volatility, OVID or INBX? Ovid Therapeutics has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. SummaryOvid Therapeutics beats Inhibrx Biosciences on 9 of the 15 factors compared between the two stocks. Get Ovid Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OVID vs. The Competition Export to ExcelMetricOvid TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.24M$3.44B$6.19B$10.56BDividend YieldN/A2.27%5.70%4.81%P/E Ratio-2.7923.0185.5427.13Price / Sales15.82481.75608.39130.24Price / CashN/A46.9237.1060.81Price / Book1.5410.4112.236.52Net Income-$26.43M-$52.77M$3.33B$276.93M7 Day Performance-11.38%2.31%1.17%1.93%1 Month Performance22.31%12.59%6.85%2.19%1 Year Performance21.31%11.18%58.93%34.62% Ovid Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OVIDOvid Therapeutics3.9844 of 5 stars$1.48-5.7%$3.70+150.0%+21.3%$105.24M$6.65M-2.7960INBXInhibrx Biosciences1.6506 of 5 stars$34.38+5.9%N/A+132.8%$470.27M$200K-3.25166ATXSAstria Therapeutics1.9211 of 5 stars$8.47+1.9%$29.50+248.3%+4.5%$468.97MN/A-4.2130Trending NewsAnalyst DowngradeCYRXCryoPort3.2917 of 5 stars$9.40+1.1%$12.56+33.6%+34.0%$465.62M$228.38M7.071,186News CoverageSLDBSolid Biosciences2.997 of 5 stars$6.01+0.8%$15.00+149.6%-10.9%$464.10M$8.09M-2.15100News CoverageAnalyst DowngradeALMSAlumis3.432 of 5 stars$4.61+3.8%$20.17+337.5%-62.7%$462.05MN/A0.00N/APositive NewsGap DownDRUGBright Minds Biosciences3.22 of 5 stars$64.97+2.7%$81.00+24.7%+33.7%$445.81MN/A-69.86N/APositive NewsLXEOLexeo Therapeutics3.0481 of 5 stars$8.20-0.5%$17.00+107.3%-13.8%$444.97M$650K-2.5258Trending NewsAnalyst ForecastInsider TradeRAPTRapt Therapeutics3.1558 of 5 stars$26.35-1.6%$24.78-6.0%+104.9%$443.05M$1.53M-1.8680Analyst RevisionGap DownAUTLAutolus Therapeutics3.5538 of 5 stars$1.65-0.6%$9.12+452.7%-66.3%$441.80M$10.12M-1.96330CGEMCullinan Therapeutics3.5628 of 5 stars$7.83+5.8%$26.00+232.1%-53.1%$437.15MN/A-2.4230News CoveragePositive NewsGap Up Related Companies and Tools Related Companies INBX Alternatives ATXS Alternatives CYRX Alternatives SLDB Alternatives ALMS Alternatives DRUG Alternatives LXEO Alternatives RAPT Alternatives AUTL Alternatives CGEM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OVID) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Ovid Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
